Federal and state regulators asked a judge to hold “pharma bro” Martin Shkreli in contempt, alleging he traded drug stocks despite a lifetime ban from the pharmaceutical industry

Impact · against what's priced in

The allegations that Martin Shkreli traded pharmaceutical stocks despite a lifetime ban do not move the needle for any specific company. While legally significant for Shkreli, the activity does not represent a material operational or financial change for the stocks he allegedly traded.

Scored by the NIS engine · methodology.

Federal and state regulators asked a judge to hold “pharma bro” Martin Shkreli in contempt, alleging he traded drug stocks despite a lifetime ban from the pharmaceutical industry

regulation
healthcare
pharmaceuticals

Federal and state regulators asked a judge to hold “pharma bro” Martin Shkreli in contempt, alleging he traded drug stocks despite a lifetime ban from the pharmaceutical industry

What matters in this story

BMY Reports Mixed Phase III Trial Results, Stock Down

Federal and state regulators asked a judge to hold “pharma bro” Martin Shkreli in contempt, alleging he traded drug stocks despite a lifetime ban from the pharmaceutical industry

What matters in this story

BMY Reports Mixed Phase III Trial Results, Stock Down

CVS Health Unit to Pay $315 Million to Resolve Illegal Opioid Prescription Claims

Track these names every morning.

Surgical Precision, Sustainable Returns: Johnson & Johnson Secures its Cash Flow Runway

5 High-Yield Dividend Stocks That Could Turn October's Market Weakness Into Income

TGTX Stock Rises 60% in 6 Months: Here's What You Should Know

Mirum's Livmarli Meets Phase III Goal in Ultra-Rare Liver Diseases

Federal and state regulators asked a judge to hold “pharma bro” Martin Shkreli in contempt, alleging he traded drug stocks despite a lifetime ban from the pharmaceutical industry

What matters in this story

Next reads from the same story arc

BMY Reports Mixed Phase III Trial Results, Stock Down

Federal and state regulators asked a judge to hold “pharma bro” Martin Shkreli in contempt, alleging he traded drug stocks despite a lifetime ban from the pharmaceutical industry

What matters in this story

Next reads from the same story arc

BMY Reports Mixed Phase III Trial Results, Stock Down

CVS Health Unit to Pay $315 Million to Resolve Illegal Opioid Prescription Claims

Track these names every morning.

Surgical Precision, Sustainable Returns: Johnson & Johnson Secures its Cash Flow Runway

5 High-Yield Dividend Stocks That Could Turn October's Market Weakness Into Income

TGTX Stock Rises 60% in 6 Months: Here's What You Should Know

Mirum's Livmarli Meets Phase III Goal in Ultra-Rare Liver Diseases